How the BAROSTIM NEO System
Is Designed to Work

3outof4england

Despite being treated with the best available therapies, three out of four people with systolic congestive heart failure die within five years of diagnosis.2

4outof5english

Studies show that four out of five people with congestive heart failure do not qualify for what is now the only currently approved device therapy (known as cardiac resynchronization therapy). You may be one of them. 3

This is why CVRx developed the investigational BAROSTIM NEO System and is conducting the BeAT-HF Study.

If you decide to learn more,click on the Am I A Candidate? button. If your answers indicate you may be a potential candidate, you will be invited to provide us with access to your medical records. If your medical records verify that you are a potential candidate, you will have the opportunity to meet with study personnel to ask questions and join the study if you so desire.

This website is intended to provide you with general information on heart failure and the investigational BAROSTIM NEO System. It is not intended to provide a medical diagnosis or treatment.

Sources:

In a recent study, 95 patients with congestive heart failure who were not previously implanted with a cardiac resynchronization device were randomized into two groups, 47 patients were implanted with the BAROSTIM NEO System and 48 were not. The implanted group showed improvement on average in1:

  • quality of life
  • exercise capacity
  • heart stress biomarkers
  • days hospitalized for congestive heart failure
  • left ventricular ejection fraction (a measure of cardiac pumping efficiency)

The type and frequency of complications reported in this recent study from implanting the BAROSTIM NEO System were similar to those from implanting a typical pacemaker.

Although the results of this early study are positive, they are not enough to prove the safety and effectiveness of the BAROSTIM NEO System.  To do so, and to obtain approval from the Food and Drug Administration (FDA) to make this therapy available to millions of Americans with heart failure, we need people like you to participate in a larger study, the BeAT-HF Study.

Source: 1. Zile MR et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.